Clinical Trial Detail

NCT ID NCT01042379
Title I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements no
Sponsors QuantumLeap Healthcare Collaborative
Indications

breast cancer

Therapies

Trebananib

Pertuzumab + Trastuzumab

Ganitumab

Cyclophosphamide + Doxorubicin + Paclitaxel

MK2206 + Trastuzumab

Trastuzumab + Trebananib

Ado-trastuzumab emtansine + Pertuzumab

Age Groups: adult

No variant requirements are available.